UCA1在膀胱癌中的表達(dá)及臨床意義

[摘要] 目的 探討UCA1 mRNA在膀胱移行細(xì)胞癌中的表達(dá)及其與病理分級、臨床分期和復(fù)發(fā)的關(guān)系。方法 采用SYBR GreenⅡ?qū)崟r(shí)熒光定量逆轉(zhuǎn)錄聚合酶鏈反應(yīng)試驗(yàn)方法檢測39例膀胱癌組織及8例膀胱正常組織中UCA1 mRNA的表達(dá)情況。結(jié)果 39例膀胱癌組織中UCA1 mRNA表達(dá)陽性39例，陽性率分別為100%;8例膀胱正常組織中UCA1 mRNA表達(dá)陽性3例，陽性率分別為37.5%;UCA1 mRNA的表達(dá)在癌組織和正常組織中的陽性率比較差異有顯著性(P<0.05);UCA 1mRNA的表達(dá)與病理分級、臨床分期和復(fù)發(fā)關(guān)系密切(P<0.05)。結(jié)論 UCA1參與了膀胱癌的發(fā)生發(fā)展過程，對膀胱癌的診斷、判斷病理分級、臨床分期和預(yù)后具有重要臨床意義。

[關(guān)鍵詞] UCA1;膀胱癌;實(shí)時(shí)熒光定量逆轉(zhuǎn)錄聚合酶鏈反應(yīng);SYBR GreenⅡ

[中圖分類號] R737.14 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1673-9701(2010)04-16-03

UCA1 Expression in Bladder Cancer and Its Clinical Significance

WANG BaosenXING JinchunZHENG Jiaxin

Department of Urology，the Affiliated Xiamen First Hospital of Fujian Medical University，Xiamen 361003，China

[Abstract] Objective To investigate the expression of UCA1 mRNA in bladder transitional cell carcinoma and its relationship with pathological grade，clinical stage and recurrence. Methods The SYBR Green II real-time fluorescent quantitative RT-PCR was used to evaluate the UCA1 mRNA expression in 39 cases of bladder transitional cell carcinoma and 8 cases of normal tissue. Results All of 39 cases of bladder transitional cell carcinoma cases showed the positive expression of UCA1 mRNA，with the positive rate of 100%，and 3 of 8 cases of normal tissue showed the positive expression of UCA1 mRNA，with the positive rate of 37.5%. There was a significant difference in the positive rate of between the two(P<0.05). There was a close relation between the pathological grade(P<0.05)， the clinical stage(P<0.05)and recurrence(P<0.05). Conclusion UCA1 is involved in the development and progression of bladder transitional cell carcinoma and it is of important clinical significance in the diagnosis of bladder transitional cell carcinoma and the judgement of pathological grade，clinical stage and prognosis.

[Key words] UCA1;Bladder cancer;Real time quantitative RT-PCR;SYBR Green Ⅱ

UCA1(urothelial carcinoma associated 1)是最近發(fā)現(xiàn)的一個(gè)新的膀胱癌的特異性非編碼基因，本文運(yùn)用SYBR GreenⅡ?qū)崟r(shí)熒光定量RT-PCR的方法檢測39例膀胱癌組織及9例膀胱正常組織中UCA1 mRNA，探討其表達(dá)與膀胱癌臨床分期和病理分級的關(guān)系，進(jìn)一步為膀胱的診斷、治療和預(yù)后提供臨床依據(jù)。

1材料與方法

1.1標(biāo)本來源

選取我院2008年10月～2009年9月術(shù)后病理證實(shí)為膀胱癌的膀胱癌標(biāo)本39份，其中膀胱腫瘤電切的標(biāo)本31份，行全膀胱手術(shù)的腫瘤標(biāo)本8份，初發(fā)28例，復(fù)發(fā)11例。所有膀胱癌患者中男32例，女7例。年齡(60.72±13.19)歲。根據(jù)腫瘤浸潤深度可分為表淺型(Tis、Ta、T1)和浸潤型，其中表淺型26例，浸潤型13例。病理情況根據(jù)WHO/ISUP分級法，其中高級別尿路上皮癌9例，低級別尿路上皮癌(包括低度惡性傾向尿路上皮乳頭瘤)30例;膀胱正常組織8份，其中1份前列腺增生患者正常膀胱組織，其余7份為膀胱腫瘤邊緣3cm以外的正常膀胱組織，其中男6份，女2份，年齡(63.75±12.45)歲?！?br>